Considerations for Industry—Preparing for the FDA Model‐Informed Drug Development (MIDD) Paired Meeting Program

• Published in: Clinical pharmacology and therapeutics Vol. 116; no. 2; pp. 282 - 288
• Main Authors: Galluppi, Gerald R., Ahamadi, Malidi, Bhattacharya, Souvik, Budha, Nageshwar, Gheyas, Ferdous, Li, Chi‐Chung, Chen, Yuan, Dosne, Anne‐Gaëlle, Kristensen, Niels Rode, Magee, Mindy, Samtani, Mahesh N., Sinha, Vikram, Taskar, Kunal, Upreti, Vijay V., Yang, Jianning, Cook, Jack
• Format: Journal Article
• Language: English
• Published: United States 01-08-2024
• ISSN: 0009-9236; 1532-6535; 1532-6535
• DOI: 10.1002/cpt.3245

A recent industry perspective published in this journal describes the benefits received by drug companies from participation in the MIDD Pilot Program. Along with the primary objectives of supporting good decision‐making in drug development, there were substantial savings in time and development costs. Furthermore, many sponsors reported qualitative benefits such as new learnings and clarity on MIDD strategies and methodology that could be applied to other development programs. Based on the success of the Pilot Program, the FDA recently announced the continuation of the MIDD Paired Meeting Program as part of the Prescription Drug User Fee Act (PDUFA VII). In this report, we describe the collective experiences of industry participants in the MIDD Program to date, including all aspects of the process from meeting request submission to follow‐up actions. The purpose is to provide future participants with information to optimize the value of the MIDD Program.